NCT05998928View on ClinicalTrials.gov

A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 27, 2023

Primary Completion Date

July 27, 2025

Study Completion Date

July 27, 2026

Conditions
Multiple Myeloma
Interventions
DRUG

Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells

"fludarabine 30 mg/m2 and cyclophosphamide 300 mg/m2 both on three consecutive days during D-7 to D-3~BCMA-GPRC5D CAR-T Cells on day 0"

Trial Locations (1)

430022

RECRUITING

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
collaborator

Guangzhou Bio-gene Technology Co., Ltd

INDUSTRY

lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER